MESO Mesoblast Limited

4.9
+0.05  (+1%)
Previous Close 4.85
Open 5.03
Price To Book 0.93
Market Cap 487468680
Shares 99,483,404
Volume 50,114
Short Ratio
Av. Daily Volume 52,468

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b Class IV primary endpoint reached 1Q 2018.
MPC-150-IM - Class IV
Chronic heart failure (CHF)
Phase 3 completion of enrollment announced March 29, 2018.
MPC-06-ID
Chronic low back pain
BLA filing due following FDA meeting in April 2019.
MSC-100-IV
acute graft versus host disease (aGVHD) in children
Phase 2 data released August 2016. Partnership required for Phase 3 development.
MPC-300-IV
Rheumatoid arthritis
Phase 3 enrolment to be completed 1Q 2019.
MPC-150-IM - Class 2/3
Heart failure
Phase 2b trial did not meet primary endpoint - November 11, 2018.
MPC-150-IM
End-Stage Heart Failure with LVADs

Latest News

  1. Mesoblast Licensee Files for Marketing Approval to Treat Epidermolysis Bullosa
  2. U.S. Healthcare Leader Joseph R. Swedish Appointed Mesoblast Chairman
  3. Mesoblast Features at Upcoming U.S. Investor Conferences
  4. Mesoblast Reports Financial Results and Operational Highlights for the First Half Ended December 31, 2018
  5. Final Patient Dosed in Mesoblast Phase 3 Trial of Revascor Cell Therapy for Advanced Heart Failure
  6. Mesoblast Financial Results Webcast for Half Year, Q2 Ended December 31, 2018
  7. New Research Coverage Highlights Symantec, YY, Workiva, Exponent, Ferroglobe, and Mesoblast — Consolidated Revenues, Company Growth, and Expectations for 2019
  8. Hercules Capital Provides US$15M From Existing Facility for Mesoblast to Accelerate Product Commercialization Programs
  9. Does The Mesoblast Limited (ASX:MSB) Share Price Tend To Follow The Market?
  10. Mesoblast Highlights 2019 Key Priorities for its Leading Cellular Medicines Pipeline at Biotech Showcase in San Francisco
  11. Phase 3 Trial of Mesoblast’s Cell Therapy in Chronic Heart Failure Completes Recruitment
  12. Mesoblast Corporate Review
  13. Mesoblast Makes Executive Appointment to Drive Product Commercialization
  14. Meetings Held With FDA Support Mesoblast’s Planned Regulatory Filing for Commercialization of Remestemcel-L in Acute GVHD
  15. Mesoblast Reports First Quarter Ended September 30, 2018 Financial Results and Operational Highlights
  16. Mesoblast Financial Results Webcast for Quarter Ended September 30, 2018
  17. Clinically Meaningful Outcome in NIH Trial of MPC-150-IM for Heart Failure LVAD Recipients Provides Pathway for Potential Regulatory Approval